Holen Sie sich die Stockscreener-App
0.4439
3.30%
0.0142
Schlusskurs vom Vortag:
$0.4297
Offen:
$0.42
24-Stunden-Volumen:
2.06M
Relative Volume:
3.35
Marktkapitalisierung:
$53.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-0.2757
EPS:
-1.61
Netto-Cashflow:
$-192.27M
1W Leistung:
-18.85%
1M Leistung:
-42.21%
6M Leistung:
-66.11%
1J Leistung:
-86.96%
1-Tages-Spanne:
$0.4043
$0.4528
1-Wochen-Bereich:
$0.4043
$0.5549
52-Wochen-Spanne:
$0.4043
$5.195
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
1601 TRAPELO ROAD, WALTHAM
Vergleichen Sie IVVD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.4439 | 53.10M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
Charles Schwab Investment Management Inc. Sells 289,312 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 74,764 Shares of Stock - MarketBeat
Invivyd director Terrance McGuire sells shares worth $147,795 By Investing.com - Investing.com South Africa
Invivyd director Terrance McGuire sells shares worth $147,795 - Investing.com
Invivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in Stock - MarketBeat
Invivyd director Terrance McGuire sells $103,384 in stock - Investing.com
Adagio Therapeutics Stock Hits 52-Week Low at $0.57 Amid Challenges - Investing.com
Fmr LLC Sells 1,046,775 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Fmr LLC Decreases Stock Holdings in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Invivyd announces board member resignation By Investing.com - Investing.com South Africa
Invivyd announces board member resignation - Investing.com
Analysts Provide An Important Insights On Invivyd Inc (IVVD) - Stocks Register
Invivyd's (IVVD) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
HC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target to $10.00 - Defense World
FY2024 Earnings Forecast for Invivyd Issued By HC Wainwright - Defense World
Adagio Therapeutics stock hits 52-week low at $0.72 By Investing.com - Investing.com Australia
Adagio Therapeutics stock hits 52-week low at $0.72 - Investing.com
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates - MSN
Invivyd (NASDAQ:IVVD) Given New $10.00 Price Target at HC Wainwright - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call Transcript - Insider Monkey
Invivyd Inc (IVVD) Quarterly 10-Q Report - Quartzy
Invivyd’s Q3 2024: Revenue Growth and Strategic Developments - TipRanks
Earnings call: Invivyd reports steady growth amid regulatory challenges - Investing.com
IVVD stock touches 52-week low at $0.81 amid market challenges - Investing.com India
Invivyd earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - The Manila Times
Invivyd's PEMGARDA Shows Promise Against COVID Variants Despite Lab Data Dispute | IVVD Stock News - StockTitan
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect - Yahoo Finance
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expe - GuruFocus.com
Invivyd (IVVD) Set to Announce Earnings on Thursday - Defense World
FMR LLC's Strategic Reduction in Invivyd Inc Shares - GuruFocus.com
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Upload - The Manila Times
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term - The Bakersfield Californian
Invivyd's COVID Drug Shows 84% Risk Reduction in Phase 3 Trial, Secures FDA Authorization | IVVD Stock News - StockTitan
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire Inc.
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - The Manila Times
Invivyd (IVVD) Sets Q3 2024 Earnings Call: Financial Results & Business Updates Coming Nov 14 | IVVD Stock News - StockTitan
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Wednesday - Benzinga
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Part - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Invivyd Inc-Aktie (IVVD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 19 '24 |
Sale |
0.43 |
152,067 |
65,951 |
3,688,079 |
| MCGUIRE TERRANCE | Director |
Dec 17 '24 |
Sale |
0.48 |
97,410 |
46,757 |
3,914,910 |
| MCGUIRE TERRANCE | Director |
Dec 18 '24 |
Sale |
0.47 |
74,764 |
35,087 |
3,840,146 |
| MCGUIRE TERRANCE | Director |
Dec 12 '24 |
Sale |
0.58 |
125,000 |
72,875 |
4,077,679 |
| MCGUIRE TERRANCE | Director |
Dec 16 '24 |
Sale |
0.47 |
65,359 |
30,510 |
4,012,320 |
| MCGUIRE TERRANCE | Director |
Dec 10 '24 |
Sale |
0.59 |
175,000 |
103,005 |
4,363,079 |
| MCGUIRE TERRANCE | Director |
Dec 11 '24 |
Sale |
0.59 |
160,400 |
94,812 |
4,202,679 |
| MCGUIRE TERRANCE | Director |
Dec 09 '24 |
Sale |
0.61 |
150,000 |
91,560 |
4,538,079 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):